David Waterhouse

21.7k total citations
175 papers, 4.9k citations indexed

About

David Waterhouse is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David Waterhouse has authored 175 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in David Waterhouse's work include Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (31 papers). David Waterhouse is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (31 papers). David Waterhouse collaborates with scholars based in United States, United Kingdom and Netherlands. David Waterhouse's co-authors include David R. Spigel, John D. Hainsworth, Howard A. Burris, Ronald B. Natale, Stephen A. Ward, F. Anthony Greco, Robert C. Whorf, Coleman K. Obasaju, Mary Varterasian and Oday Hamid and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David Waterhouse

162 papers receiving 4.7k citations

Peers

Countries citing papers authored by David Waterhouse

Since Specialization

Citations

This map shows the geographic impact of David Waterhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Waterhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Waterhouse more than expected).

Fields of papers citing papers by David Waterhouse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Waterhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Waterhouse. The network helps show where David Waterhouse may publish in the future.

Co-authorship network of co-authors of David Waterhouse

This figure shows the co-authorship network connecting the top 25 collaborators of David Waterhouse. A scholar is included among the top collaborators of David Waterhouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Waterhouse. David Waterhouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world treatment patterns, healthcare resource utilization, and healthcare costs in patients in the United States with metastatic non-small cell cancer receiving second or subsequent line systemic anticancer therapy 2025 ·Respiratory Medicine and Research ·(unknown), (unknown), David Waterhouse, (unknown), Thomas E. Delea, Björn Stollenwerk	0
2	Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation 2025 ·Advances in Therapy ·(unknown), Zhiyi Lan, David Waterhouse, Jürgen Wolf, Enriqueta Felip, (unknown), Noor Khairiah A. Karim, (unknown), Björn Stollenwerk	0
3	Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium. 2024 ·Journal of Clinical Oncology ·(unknown), James E. Butrynski, John C. Paschold, Patrick J. Ward, David Waterhouse, Alexander I. Spira, (unknown), David Hakimian, Robert M. Jotte, Timothy Larson, Michael W. Meshad, (unknown), Donald Richards, Marcus A. Neubauer, Nicholas J. Robert, (unknown), (unknown), Robert L. Coleman, David R. Spigel	1
4	Abstract 3819: Real-world long-term survival outcomes of first-line immunotherapy-based regimens in advanced non-small cell lung cancer 2024 ·Cancer Research ·David Waterhouse, (unknown), Keith A. Betts, (unknown), Yong Yuan, (unknown), (unknown), David D. Stenehjem	0
5	The state of cancer treatment trials in America: A comparison of counties with and without active trials by demography and social vulnerability. 2023 ·JCO Oncology Practice ·(unknown), Caroline Schenkel, Suanna S. Bruinooge, (unknown), Jeffrey Peppercorn, Ishwaria M. Subbiah, David Waterhouse, Laura A. Levit	1
6	MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy 2023 ·Journal of Thoracic Oncology ·Kai He, David Berz, Shirish M. Gadgeel, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, David S. Hong, Edward B. Garon, Anne M. Traynor, Peter Olson, (unknown), Xiaohong Yan, Ronald Shazer, Ticiana Leal	20
7	43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy 2022 ·Annals of Oncology ·Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, (unknown), David S. Hong, Ronald Shazer, Xiaohong Yan, (unknown), Kai He	13
8	Treatment Patterns in Patients with Metastatic Non-Small-Cell Lung Cancer in the Era of Immunotherapy 2021 ·Future Oncology ·David D. Stenehjem, Solomon J. Lubinga, Keith A. Betts, Wenxi Tang, (unknown), Yong Yuan, John Hartman, Sumati Rao, Jenny Lam, David Waterhouse	14
9	Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer 2021 ·Lung Cancer ·David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, (unknown), Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem	88
10	1029TiP Phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033) 2021 ·Annals of Oncology ·C. Lance Cowey, (unknown), T. A. Larson, David Waterhouse, Marya Chaney, (unknown)	1
11	Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy 2016 ·mBio ·Amaya L. Bustinduy, David Waterhouse, José Carlos Sousa-Figueiredo, Stephen K. Roberts, Aaron Atuhaire, Govert J. van Dam, Paul L. A. M. Corstjens, J. T. Scott, Michelle C. Stanton, Narcis B. Kabatereine, Stephen A. Ward, William Hope, J. Russell Stothard	61
12	Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts 2016 ·Annals of Oncology ·Ben George, Karen Kelly, Amy Ko, Hatem Soliman, (unknown), Zev A. Wainberg, David Waterhouse, Peter J. O’Dwyer, Howard S. Höchster	2
13	A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC) 2016 ·Annals of Oncology ·Melissa L. Johnson, Volker Wacheck, Maen Hussein, Michael McCleod, Davey B. Daniel, David Waterhouse, (unknown), Donald K. Strickland, Johanna C. Bendell	3
14	PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC 2016 ·Journal of Thoracic Oncology ·George R. Blumenschein, Jason C. Chandler, Edward B. Garon, David Waterhouse, Jonathan W. Goldman, Vijay Gunuganti, Ralph V. Boccia, David R. Spigel, John A. Glaspy, Donald A. Berry, Beata Korytowsky, Jin Zhu, Wen Lin, Kelly L. Bennett, Craig H. Reynolds	4
15	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment 2014 ·Journal of Clinical Oncology ·Jeffrey S. Weber, Laura A. Levit, Peter C. Adamson, Suanna S. Bruinooge, Howard A. Burris, Michael A. Carducci, Adam P. Dicker, Mithat Gönen, Stephen J. O’Keefe, Michael A. Postow, Michael A. Thompson, David Waterhouse, Susan Weiner, Lynn M. Schuchter	81
16	PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·Ralph Zinner, Coleman K. Obasaju, David R. Spigel, Robert Weaver, J. Thaddeus Beck, David Waterhouse, Manuel Modiano, Borys Hrinczenko, Petros Nikolinakos, Jingyi Liu, Andrew Koustenis, Katherine B. Winfree, Symantha Melemed, Susan C. Guba, Waldo Ortuzar, D. Desaiah, Joseph Treat, Ramaswamy Govindan, Helen J. Ross	120
17	Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75 2011 ·Journal of Clinical Oncology ·Noah M. Hahn, Walter M. Stadler, Robin Zoň, David Waterhouse, Joel Picus, Sreenivasa Nattam, Cynthia S. Johnson, Susan M. Perkins, (unknown), Christopher J. Sweeney	147
18	Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma 2010 ·Journal of Clinical Oncology ·John D. Hainsworth, David R. Spigel, Howard A. Burris, David Waterhouse, Bobby L. Clark, Robert C. Whorf	135
19	Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group 2009 ·Journal of Thoracic Oncology ·Shadia I. Jalal, David Waterhouse, Martin J. Edelman, Sreenivasa Nattam, Rafat Ansari, (unknown), (unknown), Mark Richards, Jingwei Wu, Menggang Yu, (unknown), Angela White, Nasser H. Hanna	12
20	Three new landbirds from the early Paleogene of Denmark 2004 ·ePrints Soton (University of Southampton) ·Gareth J. Dyke, David Waterhouse, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact